Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022

Table of Contents

1. Hemophilia A Treatment Market Summary
2. Hemophilia A Treatment Overview
   1. Disease Definition
   2. Hemophilia Types
      1. Mild
      2. Moderate
      3. Severe
   3. Disease Symptoms
3. Current Diagnosis Patterns
4. Treatment Patterns of Hemophilia A
   1. Treatment Guidelines for Hemophilia A
5. Hemophilia A treatment Epidemiology -Prevalent Population & Segmentations
   1. Prevalent Population Globally (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
   2. Prevalent Population in the United States (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
   3. Prevalent Population in Germany (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
   4. Prevalent Population in France (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
   5. Prevalent Population in Italy (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
   6. Prevalent Population in Spain (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
   7. Prevalent Population in United Kingdom (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
   8. Prevalent Population in Japan (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
6. Current and Future Approaches of Care in Hemophilia A Treatment
   1. Pre-replacement Therapy
   2. Replacement Therapy
      1. On Demand
      2. Prophylaxis
   3. Non-Replacement Therapy
      1. Mimetics/Agonists
   4. Gene Therapy
7. Marketed Drugs & Sales Forecast in Hemophilia A Treatment
   1. CSL Behring: Afstyla (Antihemophilic Factor (Recombinant), Single Chain)
      1. Product Profile
      2. Safety & Efficacy
      3. Afstyla Sales Forecast-2016-2022
   2. Biogen IDEC: Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
      1. Product Profile
      2. Safety & Efficacy
      3. Eloctate Sales Forecast-2016-2022
   3. Genentech: Hemlibra (emicizumab-kxwh)
      1. Product Profile
      2. Safety & Efficacy
      3. Hemlibra Sales Forecast-2016-2022
   4. Bayer: Kogenate FS (Antihemophilic Factor Recombinant)
      1. Product Profile
      2. Safety & Efficacy
      3. Kogenate FS Sales Forecast-2016-2022
   5. Bayer: Kovaltry [Antihemophilic Factor (Recombinant)
      1. Product Profile
      2. Safety & Efficacy
      3. Kovaltry Sales Forecast-2016-2022
   6. Octapharma: Nuwiq (recombinant Factor VIII)
      1. Product Profile
      2. Safety & Efficacy
      3. Nuwiq Sales Forecast-2016-2022
   7. Shire (Baxter): Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence]
      1. Product Profile
      2. Safety & Efficacy
      3. Obizur Sales Forecast-2016-2022
8. Market Size & Forecast of Hemophilia A Treatment(2016-2022)
   1. Market Forecast by Disease Care
      1. Prophylaxis-Market Forecast (2016-2022)
      2. On-demand therapy-Market Forecast (2016-2022)
      3. Inhibitor therapy- Market Forecast (2016-2022)
   2. Market Forecast by G7 Countries (2016-2022)
      1. United States- Market Forecast (2016-2022)
      2. Germany- Market Forecast (2016-2022)
      3. France-Market Forecast (2016-2022)
      4. Italy- Market Forecast (2016-2022)
      5. Spain- Market Forecast (2016-2022)
      6. United Kingdom- Market Forecast (2016-2022)
      7. Japan- Market Forecast (2016-2022)
9. Factors Driving the Market of Hemophilia A Treatment
10. Factors Restraining the Market of Hemophilia A Treatment
11. About Polaris Market Research
12. Disclaimer
13. Sales Support